Taiwan Liposome Company (TLC)

65 articles with Taiwan Liposome Company (TLC)

• TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

  5/26/2021

  TLC and Zydus Healthcare Limited announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ in India.

• TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

  5/25/2021

  TLC announced that the Central Drugs Standard Control Organization of India has approved the New Drug Application of Amphotericin B Liposome for Injection 50mg for immediate importation per approved usage and indication, to aid in the country’s emergency of acute liposomal amphotericin B shortage.

• InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19

  5/23/2021

  InspirMed Inc., a subsidiary of TLC that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine Congress.

• TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years RunningPraised as benchmark for small and medium-sized enterprises

  5/3/2021

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that it once again ranks in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation and Taipei Exchange listed companies.

• InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress

  4/26/2021

  InspirMed Inc. announced that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine Congress.

• TLC to Present at Upcoming Virtual Investor Conferences - Mar 02, 2021

  3/2/2021

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s management team will be presenting at the following virtual investor conferences:

• TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update

  2/5/2021

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the fiscal year ended December 31, 2020 and provided a business update.

• TLC Announces Completion of US$15 Million Financing for Subsidiary InspirMed Inc.

  1/4/2021

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that its subsidiary, InspirMed Inc., has completed a round of financing, raising US$15 million in cash from strategic investors in exchange for subsidiary equity.

• TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

  12/28/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that patient enrollment of EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis knee pain, has been completed.

• TLC Provides Corporate Update at Investor Conference - Dec 18, 2020

  12/18/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, held a virtual investor conference earlier under the invitation of KGI Securities, and provided an update on the company’s pipeline as well as corporate strategy for the year ahead.

• TLC Reports Third Quarter 2020 Financial Results and Provides Business Update

  10/28/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the third quarter ending September 30, 2020, and provided a business update.

• TLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business Officer

  10/21/2020

  TLC, a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the appointment of Thomas H. Bliss, Jr., MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development.

• TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)

  10/14/2020

  TLC announced that the first subject has been enrolled in the Phase I clinical trial of TLC19 for treatment or prophylaxis of Coronavirus disease 2019.

• TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19Dual government support in streamlined development of anti-COVID-19 therapy

  10/7/2020

  TLC announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee in Australia for the Company’s Phase I clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension for Coronavirus disease 2019.

• TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

  9/21/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 23, 2020 at 9:10am ET.

• TLC to Present at Cantor Virtual Global Healthcare Conference - Sep 11, 2020

  9/11/2020

  TLC announced that George Yeh, President of TLC, will be discussing recent activities regarding the company in a fireside chat with Kristen Kluska, Research Analyst, at Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 10:00am ET.

• TLC to Present at HC Wainwright & Co. 22nd Annual Global Investment Conference

  9/9/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET.

• TLC to Present at Baird’s 2020 Global Healthcare Conference

  9/3/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that George Yeh, President of TLC, will be presenting the latest updates on the company in a fireside chat with Madhu Kumar, Senior Research Analyst, at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 8:30am ET.

• TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China

  8/26/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in conjunction with 3SBio, announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted its Marketing Authorization Application for Ampholipad™, TLC’s complex generic of Gilead’s AmBisome® used for the treatment of systemic fungal infections.

• TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19

  8/14/2020

  TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced the submission of an Investigational New Drug Application to the Taiwan Food and Drug Administration for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus disease 2019.